Download PDF
Kardiologie up2date 2016; 12(03): 220-223
DOI: 10.1055/s-0042-114864
Hotline – Koronare Herzerkrankung und Atherosklerose
© Georg Thieme Verlag KG Stuttgart · New York

SGLT2-Hemmung und Reduktion kardiovaskulärer Ereignisse bei Diabetes

Katharina Schütt
,
Nikolaus Marx
Further Information

Publication History

Publication Date:
29 September 2016 (online)

Also available at
    Permissions and Reprints All articles of this category

Abstract

SGLT2-inhibitors are a novel class of antidiabetic drugs that increase urinary glucose excretion thus lowering blood glucose levels. In addition to their glucose-lowering properties, these agents reduce weight and blood pressure and seem to exhibit additional beneficial effect in the cardiovascular system. The recently published EMPA-REG OUTCOME study demonstrated a reduction in cardiovascular mortality, overall mortality as well as hospitalisation for heart failure by the SGLT2-inhibitor empagliflozin in a population of patients with type 2 diabetes and high cardiovascular risk.

 

  • Literatur

  • 1 Di Angelantonio E, Kaptoge S. Emerging Risk Factors C et al. Association of Cardiometabolic Multimorbidity With Mortality. JAMA 2015; 314: 52-60
    CrossrefPubMedGoogle Scholar
  • 2 Chao EC, Henry RR. SGLT2 inhibition--a novel strategy for diabetes treatment. Nature reviews Drug discovery 2010; 9: 551-559
    CrossrefPubMedGoogle Scholar
  • 3 Rahmoune H, Thompson PW, Ward JM et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-3434
    CrossrefPubMedGoogle Scholar
  • 4 Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011; 32: 515-531
    CrossrefPubMedGoogle Scholar
  • 5 Whalen K, Miller S, Onge ES. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes. Clin Ther 2015; 37: 1150-1166
    CrossrefPubMedGoogle Scholar
  • 6 Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128
    CrossrefPubMedGoogle Scholar
  • 7 [Anonym] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389
    PubMedGoogle Scholar
  • 8 Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153
    CrossrefPubMedGoogle Scholar
  • 9 Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; DOI: 10.1056/NEJMoa1515920.
    PubMedGoogle Scholar